1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6DC47FDAB6A6E5786002587290047D7EE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/leveraging-outcomes-data-operational-roles-health-economics-outcomes-research-cns-products
18
19
203.239.58.199
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Medical Affairs Health Outcomes

Leveraging Outcomes Data - Operational Roles in Health Economics & Outcomes Research for CNS Products

ID: POP-339


Features:

9 Info Graphics

29 Data Graphics

570+ Metrics

1 Narratives


Pages: 50


Published: 2021


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Demonstrating a CNS product’s value proposition and its potential in real-world practice is integral to maximizing clinical and market success. The Health Economics Outcomes Research (HEOR) function is an important player in generating value-oriented outcomes data, but success revolves around effective internal collaboration, optimal launch investment in HEOR activities, setting performance indicators, maintaining effective staffing ratios, and other key operational questions.

Best Practices, LLC undertook this benchmarking research to identify how leading CNS manufacturers develop successful Health Outcomes groups. This report investigates specific ways that the HEOR function drives decision-making and delivers value across medical activities. It also probes winning strategies used for effective health outcomes data communication and utilization, stakeholder collaboration, and launch investment timelines for new CNS therapies. Finally, the report also examines the critical advantages of - and top challenges for - a successful HEOR program.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Communications


Companies Profiled:
AbbVie; Alexion Pharmaceuticals; Bayer; Brii Biosciences; CSL Behring; Eisai; Greenwich Biosciences; Harmony Biosciences; Lundbeck; Merck; Novartis; Nucleus Global; Pfizer; Takeda Pharmaceuticals

Study Snapshot

Best Practices, LLC engaged 16 executives from 14 pharmaceuticals offering CNS products. The study insights are mostly from directors and higher management executives, representing around ninety percent of the participants.

Key topics covered in this report include:

  • HEOR involvement and its effectiveness in delivering value
  • Health outcomes data usage and its effectiveness
  • Role of HEOR in CNS health outcomes activities and data collection
  • KPIs to measure success of HEOR
  • Technology and tools used to demonstrate value
  • Challenges and success factors in working with payers for CNS products

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Launch Investment:
    • Early-stage lifecycle investments (<Phase III) build competitive advantage to maximize ROI and optimize commercial success.
    • Mature commercial groups focus on early-stage HEOR investments to balance clinical and economic value propositions in drug development. Medical Affairs is slow to begin optimal launch investment.
  • Training & KPIs: Expanding HEOR roles to support drug development and research collection require training on a quarterly and semi-annually basis. Effective HEOR programs measure impact via KPIs. 43% of respondents optimistic about tracking RWD in the future.

Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive Summaryp. 3-7
Research Objectives & Methodologyp. 5
Participating Companies & Titlesp. 6
Segmentation Criteriap. 7
II.
HEOR Structure, Collaboration and Involvementp. 8-21
III.
Launch Investment for HEOR Activitiesp. 22-23
IV.
Technology and Toolsp. 24-28
V.
Training and KPIs Measurementp. 29-32
VI.
HEOR Staffing and Leadershipp. 33-36
VII.
Lessons Learned, Success Factors and Pitfallsp. 37-40
VIII.
Participant Demographicsp. 41-43
IX.
Appendixp. 44-49
X.
About Best Practices, LLCp. 50

    List of Charts & Exhibits

    I. HEOR Structure, Collaboration and Involvement

    • Structure of CNS Health Economics and Outcomes Research (HEOR) group within the organization
    • HEOR involvement vs. effectiveness for value delivery
    • HEOR effectiveness at delivering value
    • HEOR effectiveness at delivering value – Market Access vs. Medical Affairs
    • Health outcomes data usage vs. effectiveness
    • Utilization of listed types of health outcomes activities by the HEOR function
    • Utilization of listed types of health outcomes activities by the HEOR function – Market Access vs. Medical Affairs
    • Health outcomes activity effectiveness
    • HEOR involvement level in each of the listed activities
    • Sharing of medical information with various groups
    • Organization’s role in health outcomes data collection
    • Preferred frequency of communications (at a country & region level) with internal staff
    • Roles played by HEOR team in carrying out activities designed to probe (payers) stakeholders’ needs and perspectives

    II. Launch Investment for HEOR Activities

    • Point at which investment is started and point at which maximum investment is reached in the listed HEOR activities to develop value assessments for new CNS therapies

    III. Technology and Tools

    • Highly effective technologies for field communication
    • Frequency of technology updates
    • Annually updated technologies
    • Tools used by HEOR group to demonstrate value/ communicate with payers

    IV. Training and KPIs Measurement

    • Training and development programs that work best for HEOR groups
    • Frequency of training provided to Health Outcomes groups
    • Effective KPIs and metrics to measure the success of real world data program

    V. HEOR Staffing and Leadership

    • Number of field staff that work in the HEOR organization and number of field-based staff dedicated to HEOR structure
    • Number of field staff that work in the HEOR organization and number of field-based staff dedicated to HEOR structure – Market Access vs. Medical Affairs
    • Leadership level of the CNS HEOR group

    VI. Lessons Learned, Success Factors and Pitfalls

    • Top advantages to pursuing HEOR planning earlier in the R&D cycle
    • Top success factors for HEOR in developing and maintaining strong capabilities for work with payer groups
    • Topmost difficult challenges / pitfalls for HEOR in developing and maintaining strong capabilities for work with payer groups

    VII. Participant Demographics

    • Geographic span of HEOR responsibility within participating companies
    • Job titles of benchmark participants